AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03183765
Drug: Measles-Mumps-Rubella Vaccine
RxNorm normalized name: MEASLES/MUMPS/RUBELLA VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR vaccine will be injected 0.5 ml into the largest wart at 2-week intervals until complete clearance was achieved or for a maximum of 3 treatments.~Response to treatment will be evaluated 1 month after the last session by decrease in the size of warts, decrease in the number of warts and photographic comparison. The clinical response was graded into complete (complete cure), partial (if there was a decrease in the size and\\or a decrease in the total number of warts), and no response (no change in size and number of warts).
Trial: NCT00002798
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002798
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT
Trial: NCT00002798
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01333722
Drug: Hydrocodone/Acetaminophen Extended Release
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01333722
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT04587206
Drug: CKD-828, D097, D337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO
Trial: NCT01433510
Drug: Grazax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet/day - pre and co-seasonal
Trial: NCT00699062
Drug: singular
RxNorm normalized name: ALCOHOL 70 mL in 100 mL TOPICAL CLOTH [Singular Wipes]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants randomized into this arm will receive singular 10mg q.n. plus combine therapy with inhaled ICS+LABA
Trial: NCT00699062
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants allocated into this arm will receive placebo 10mg,q.n plus combine therapy with inhaled ICS+LABA
Trial: NCT00003846
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00784368
Drug: ITCZ Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITCZ syrup product containing ITCZ 10 mg per ml in dose range of 20 ml to 40 ml daily for 7 days up to 12 weeks
Trial: NCT00784368
Drug: ITCZ-IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg IV twice daily for 2 days and once daily for the next 1 to 12 days
Trial: NCT01602250
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 8 mg/min ropivacaine 8 mg/min
Trial: NCT01602250
Drug: Intralipid®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 8 mg/min ropivacaine 8 mg/min Intralipid® 120 ml in one min
Trial: NCT00405873
Drug: AMT2003
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02457650
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On days -7 through -6, Cyclophosphamide 60mg/kg/day IV will be infused over 60 minutes.
Trial: NCT02727322
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01356862
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONE INJECTION OF PLACEBO 10 TO 7 DAYS BEFORE SURGERY
Trial: NCT01470131
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT01343745
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pressurised metered dose inhaler
Trial: NCT00959426
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be given placebo or PF-04620110. Anticipated total daily doses for Cohorts A, B, C, D, E, F and G are 1, 3, 5, 10 and 20 mg. In each Cohort 9 subjects will receive active treatment and 3 will receive placebo for 14 days. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses during the study based on ongoing safety, tolerability and PK results, but will not be projected to exceed established PK stopping criteria.
Trial: NCT00913510
Drug: Anticholinergic medication
RxNorm normalized name: Anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, i.e. Drug.
Trial: NCT02329743
Drug: RX-10045
RxNorm normalized name: BARRIER,SENSURA COLOPLAST #10045
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical therapy
Trial: NCT00856609
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05524077
Drug: Anti-arrhythmic Drugs (AADs)
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care usually encompasses patients who have not previously had AADs, being commenced on sotalol 80mg twice/day. Lower doses may be initiated by treating doctor, as clinically indicated. If there is contraindication to sotalol, another beta-blocker may be initiated using standard doses. Clinicians may consider alternative AADs if there is contraindication to beta-blockers. Doses would be up titrated to the maximal tolerated amount.~For patients already on an AAD, amiodarone would usually be added, as per VANISH trial.~They will receive a loading dose 400mg twice/day for 2 weeks, followed by 400mg/day for 4 weeks and 200mg/day thereafter. Patients who have failed amiodarone dose \<300mg/day will receive a repeat loading dose of 400mg twice/day for 2 weeks, followed by 400mg/day for 1 week, and 300mg/day thereafter.~If the treating doctor decides to do a CA for VT, the occurrence and timepoint of cross-over will be recorded. Cross-over is estimated to be \<2% (VANISH trial).
Trial: NCT02605356
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00185237
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch
Trial: NCT00473889
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vorinostat 400 mg placebo capsules once daily. Up to 6 months of treatment
Trial: NCT03063476
Drug: C-13 labeled Lysine
RxNorm normalized name: Urea C 13
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Carbon-13 is a stable naturally occurring heavy isotope of carbon. Inclusion of a 13C label on lysine allows for subsequent differentiation between endogenous and exogenous lysine and 2-AAA for calculation of clearance and excretion of the lysine bolus.
Trial: NCT03063476
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Because patients will have multiple blood draws during the course of the study, subjects will have an IV placed to reduce the number of needle sticks. To keep the vein open for blood collections, we will infuse Normal (0.9%) Saline (NS) at a rate of approximately 10ml/hr in order to keep the line open.
Trial: NCT04365686
Drug: Ketofol as induction agent
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who received propofol (1mg/kg) plus ketamine (0.5mg/kg) at the induction of general anesthesia
Trial: NCT02652910
Drug: CD19.CAR-T cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retroviral vector-transduced autologous T cells to express CD19-specific CARs
Trial: NCT02433912
Drug: 750 mg paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days
Trial: NCT01960283
Drug: Methotrexate (Novatrex ®) + anti-H1
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (Novatrex ®) tablets 2.5 mg methotrexate 0.2 mg/kg/week as a single dose, orally for 8 weeks.~After 8 weeks, if the treatment is still not efficient, the dose will be increased to 0.25 mg/kg/week and continued until W18.~For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and methotrexate will be added in this group.
Trial: NCT03812744
Drug: Placebo Oral Capsule [CEBOCAP]
RxNorm normalized name: Placebo Oral Capsule [CEBOCAP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silica Oxide
Trial: NCT01960283
Drug: Placebo + anti-H1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 0.2 mg / kg / week as a single dose, orally for 8 weeks. After eight weeks, if the patient is still very embarrassed, the dose is increased to 0.25 mg / kg / week in a weekly dose.~For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and the placebo of methotrexate will be added in this group.
Trial: NCT00856635
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injected daily subcutaneously
Trial: NCT01533727
Drug: Autologous CIK Transfusion plus Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vinorelbine 25-30mg/m2 d1, d8 q3w; DDP 75mg/m2 d1 q3w; pemetrexed 500mg/m2 d1 q3w; carboplatin AUC 5/6 q3w; CIK infusion D14 q3w
Trial: NCT01533727
Drug: chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vinorelbine 25-30mg/m2 d1, d8 q3w; DDP 75mg/m2 d1 q3w; pemetrexed 500mg/m2 d1 q3w; carboplatin AUC 5/6 q3w;
Trial: NCT04393038
Drug: ABX464
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABX464 50mg QD for 28 days + Standard of Care
Trial: NCT04393038
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 50mg QD for 28 days + Standard of Care
Trial: NCT03325322
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00410189
Drug: ZD6474
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg by mouth daily for 28 Days.
Trial: NCT03618667
Drug: GC1118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC1118 (4mg/kg) will be administered by IV infusion once per week for 4 weeks(28-day cycles) up to 6 cycles, or till progression or uncontrolled toxicity.
Trial: NCT01673659
Drug: Placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04462029
Drug: BR4002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Administration to the T1 group: 5 mg of BR4002 (patch) will be attached using an applicator for 24 hours~* Administration to the T2 group: 5 mg of BR4002 (patch) will be attached without using an applicator for 24 hours
Trial: NCT04462029
Drug: BR4002-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration to the R group: 5 mg of BR4002-1 (oral formulation) will be administered with 150 mL of water
Trial: NCT00118274
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01206881
Drug: pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg/m2, IV, day 1 every 21 days, 4 cycles
Trial: NCT02192567
Drug: DS-5573a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step 1 of this study will use a starting intravenous (IV) dose of 0.1 mg/kg. Eight dose levels are planned, level 1: 0.1 mg/kg, level 1.5: 0.1 mg/kg, 0.3 mg/kg, level 2: 0.3 mg/kg, level 3: 1 mg/kg, level 4: 3 mg/kg, level 5: 10 mg/kg, level 6: 20 mg/kg, level 7: 30 mg/kg.~Step 2: 30 subjects will use the dose determined in Step 1.
Trial: NCT01138085
Drug: GSK1120212
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEK inhibitor
Trial: NCT01138085
Drug: GSK2141795
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKT Inhibitor
Trial: NCT02776046
Drug: Conventional FiO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional FiO2 with a perioperative open lung strategy
Trial: NCT03190798
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Canagliflozin
Trial: NCT03288454
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline for injection
Trial: NCT00463086
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A self-administered dose of 5mg/kg of placebo (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
Trial: NCT02137642
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double blind placebo will be delivered once by injection during study procedure.
Trial: NCT01063348
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules taken in same amount of pills as the active medication.
Trial: NCT02141672
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04301661
Drug: Switch
RxNorm normalized name: Universal Footswitch Covers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who are planning to switch from abacavir/lamivudine as part of standard HIV care will change therapy to per the discretion of their HIV provider.
Trial: NCT02172391
Drug: Placebo inhalation powder capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01103440
Drug: Antiplatelet Therapy (ASA, Clopidogrel)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiplatelet PCI treatment
Trial: NCT00114127
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60mg placebo 1x per day
Trial: NCT03072043
Drug: APR-246
RxNorm normalized name: PrameGel Reformulated Apr 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1b: Dose escalation of APR-246 via intravenous (IV) infusion, with starting dose of 50 mg/kg lean body weight (LBW). Phase 2: APR-246 at maximum tolerated dose (MTD).
Trial: NCT01466205
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mls of saline is administered over 30 minutes at approximately 11:00AM on each of three consecutive days of administration. Additional saline will be co-administered to ensure hydration.
Trial: NCT04571060
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of matching placebo
Trial: NCT02186483
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin, 20 mg, once daily
Trial: NCT02186483
Drug: Metformin and Rosuvastatin
RxNorm normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Metformin, 1000mg, once daily Rosuvastatin, 20mg, once daily
Trial: NCT01736033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet(0.2mg) orally q.d.
Trial: NCT03040128
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: high-dose, intravenous minocycline
Trial: NCT03328832
Drug: Floseal®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Floseal® (Hemostatic matrix, 10ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 10 mL vial containing the active product (Floseal®) was used. The HM remained in place for 3 minutes and was then gently rinsed from the knee as recommended by the manufacturer (Baxter)
Trial: NCT00405730
Drug: Nepafenac 1mg/ml eye drops, suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop in the study eye 3 times daily for 23 days
Trial: NCT00405730
Drug: Ketorolac Trometamol 5 mg/ml eye drops, solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop in the study eye 3 times daily for 23 days
Trial: NCT03192137
Drug: ISV-305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone in DuraSite® 2 twice daily for 16 days
Trial: NCT02799589
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mcg/kg over 1 min followed by an infusion (0.05-0.5 mcg/kg/min)
Trial: NCT03332576
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PO BID
Trial: NCT02574130
Drug: Amikacin
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg, nebulizer, every 12 hours, 10 days
Trial: NCT01060254
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 28 days for up to 12 wks
Trial: NCT01830348
Drug: DSC127
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever is sooner
Trial: NCT01830348
Drug: placebo vehicle gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01653444
Drug: GC1119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: biweekly, IV infusion
Trial: NCT02574130
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 4 ml, nebulizer, every 12 hours, 10 days
Trial: NCT01949129
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: as part of conditioning 60 mg/kg BW 2 days or as GvHD Prophylaxis 50mg/kg BW/d 2 days with Mesna
Trial: NCT01949129
Drug: Grafalon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MD: 15mg/kg BW/d 3 days MMD: 10mg/kg BW/d 3 days
Trial: NCT02012218
Drug: ADT
RxNorm normalized name: Radtue
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01371058
Drug: policosanol plus dual antiplatelet
RxNorm normalized name: POLICOSANOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aspirin 300 mg/d for 1 month followed by 100 mg/d chronically； clopidogrel 75 mg/d for at least 1 year policosanol 40mg/d for 6 months
Trial: NCT03186625
Drug: Placebo Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo granule has the same as Compound Panax Notoginseng Granule in the appearance, shape,colour,taste,frequency and duration.
Trial: NCT02171143
Drug: ASP2409
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous (IV)
Trial: NCT02171143
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous (IV)
Trial: NCT02623205
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To reduce the burden of the patients on placebo, the placebo trial will have a target of 8 weeks. To provide an opportunity for placebo non-responders to receive active drug and to aid in recruitment, we will provide 8-12 weeks of SSRI treatment to placebo non-responders. This treatment option is something offered to participants outside the clinical trial, and therefore was not treated as part of the main study.
Trial: NCT01569815
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 400 mg once daily
Trial: NCT02269696
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equal of volume compared to metoprolol.
Trial: NCT02361645
Drug: Ketorolac 0.5% eyedrops
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02116842
Drug: 40 µg fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given with different doses of bupivacaine in epidural block.
Trial: NCT01890265
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for infusion
Trial: NCT00360178
Drug: Valsartan plus Hydrochlorothiazide
RxNorm normalized name: hydrochlorothiazide / valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00360178
Drug: Candesartan plus Hydrochlorothiazide
RxNorm normalized name: candesartan / hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04162470
Drug: REGN3918
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) every week (QW) over the treatment period
Trial: NCT04178187
Drug: Caps Lactolevure
RxNorm normalized name: silica, trimethylsilyl capped
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One group will receive Caps Lactolevure x2 and the other group Caps Placebo x2.
Trial: NCT04178187
Drug: Caps Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caps Placebo
Trial: NCT02361645
Drug: Indomethacin 0.5% eyedrops
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02361645
Drug: Bromfenac 0.09% eyedrops
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02361645
Drug: Nepafenac 0.1% eyedrops
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03360760
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60mg/m\^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
Trial: NCT03360760
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: High dose of methotrexate (8-12g/m\^2), in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
Trial: NCT00977886
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, 10 days
Trial: NCT00977886
Drug: ELB353
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, 10 days
Trial: NCT01541488
Drug: Placebo to BI 1021958
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRD part: oral administration in fasted state, FE part: oral administration in fasted state and after standard high fat breakfast